Social:

Facebook Instagram Linkedin
IPA

Philanthropy, Passion & Education International Perfusion Association The International Perfusion Association (IPA), a 501(c)(3) non-profit organization, is dedicated to enhancing education and supporting global cardiac surgery initiatives. Our mission is to amplify our philanthropic efforts by organizing cardiac surgery missions, assisting those engaged in similar endeavors, and bolstering local educational programs. We welcome individuals who are eager to make a meaningful difference in the world to join us in our cause. Make a Donation
Logo

Heart to Heart Mission

For more than 20 years, the IPA has performed life-saving heart surgery on over 400 patients in Santiago, Dominican Republic.

Read More
Logo

Ecuador Mission

The IPA is working with Harvard / MGH to expand their heart surgery mission program in Ecuador. We have a mission trip planned for October 2026. Stay tuned for more information.

Read More
Logo

Your Mission Trip

The IPA will gladly make donations to qualified charitable organizations who perform cardiac surgery mission work for patients in need.

Read More

700+ Patients

Help Mend a Heart!

Every member of our team is an unpaid volunteer, so please take comfort in knowing that 100% of all donated funds go directly to patient care. Your generosity is so very welcome and will help save lives!
Make a Donation

— Latest News —

Sevoflurane Delivery During Cardiopulmonary Bypass

Estimated End-Tidal Sevoflurane Concentration to Maintain Optimal Anesthetic Depth During Cardiopulmonary Bypass: A Meta-Analysis

This meta-analysis examined how much end-tidal sevoflurane is needed to maintain appropriate anesthetic depth during cardiopulmonary bypass. Across five prospective studies involving 129 adults, the pooled estimate was 0.88 vol% for a BIS target of 40–60. Older patients required less sevoflurane, while body temperature did not significantly change dosing needs. The findings offer a practical reference point, although evidence certainty remained limited by heterogeneity and small study sizes.

READ MORE
March 29, 2026
Mechanical Circulatory Support in Cardiogenic Shock

Mechanical Circulatory Support in Cardiogenic Shock: A Contemporary Head-to-Head Comparison

This mini review compares the three main temporary mechanical circulatory support options for cardiogenic shock: Impella, venoarterial extracorporeal life support (VA-ECLS), and intra-aortic balloon pump (IABP). It explains each device’s physiology, indications, risks, and evidence base, then proposes practical algorithms for selection, escalation, de-escalation, and anticoagulation to help clinicians tailor support to shock severity and cause.

READ MORE
March 28, 2026
Safer Bypass: Oxygenator Design and Delirium Risk in CABG

Oxygenator-Related Gaseous Microemboli and Postoperative Delirium After On-Pump Coronary Artery Bypass Grafting: A Prospective Cohort Study

This prospective cohort study examined 102 adults undergoing first-time isolated on-pump CABG and compared three membrane oxygenators: Capiox FX25, Inspire 8, and Inspire 8F. The Capiox FX25 showed the lowest arterial gaseous microemboli volume and the best volume reduction, while postoperative delirium occurred in 29.4% overall and was least frequent with Capiox FX25. The findings suggest oxygenator choice may influence neurocognitive outcomes after cardiac surgery.

READ MORE
March 28, 2026
Ranolazine and Cardioprotection During Myocardial Ischemia

Cardioprotective Effects of Ranolazine in Myocardial Infarction Mediated by Stimulation of the Endogenous Mediators Involved in Ischemic Preconditioning

This experimental rat-heart study tested whether ranolazine protects the myocardium through pathways similar to ischemic preconditioning. Using a Langendorff ischemia-reperfusion model, ranolazine reduced infarct size, LDH, CK-MB, troponin I, and improved ventricular function. These benefits were lost when nitric oxide, adenosine, bradykinin, or ATP-sensitive potassium channel pathways were blocked, supporting their role in ranolazine-mediated cardioprotection.

READ MORE
March 26, 2026
Bright Neonatal ECMO Team Managing Oxygen Targets

Impact of Early Hyperoxia on Outcomes During Neonatal and Pediatric Veno-Arterial Extracorporeal Life Support

This single-center retrospective cohort study examined 229 neonatal and pediatric VA-ECLS patients and found that early hyperoxia was common, affecting 79% of cases. Severe hyperoxia, defined as PaO2 above 300 mmHg, was linked to more cardiovascular or renal complications, but it was not independently associated with in-hospital mortality, acute kidney injury, or worse functional outcomes after adjustment. The authors support standardized oxygen targets during VA-ECLS.

READ MORE
March 26, 2026
OCEAN Trial Crossroads: M-TEER in Advanced Heart Failure

Outcomes of Transcatheter Edge-to-Edge Repair in Potentially Favorable Candidates for Left Ventricular Assist Device: Evidence From the OCEAN-Mitral Registry

This study evaluated mitral transcatheter edge-to-edge repair (M-TEER) in advanced heart failure patients who might otherwise have been reasonable candidates for left ventricular assist device (LVAD) therapy. Among 129 such patients from the OCEAN-Mitral Registry, procedural success was high at 96%, but long-term outcomes were less reassuring, especially in those with marked left ventricular enlargement. Larger LV size predicted cardiovascular death after M-TEER.

READ MORE
March 26, 2026
Load More
No more posts to show